List of Excipients in Branded Drug QELBREE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Supernus Pharmaceuticals Inc	QELBREE	viloxazine hydrochloride	17772-131	ALCOHOL	2035-04-02
Supernus Pharmaceuticals Inc	QELBREE	viloxazine hydrochloride	17772-131	AMMONIA	2035-04-02
Supernus Pharmaceuticals Inc	QELBREE	viloxazine hydrochloride	17772-131	BUTYL ALCOHOL	2035-04-02
Supernus Pharmaceuticals Inc	QELBREE	viloxazine hydrochloride	17772-131	D&C YELLOW NO. 10	2035-04-02
Supernus Pharmaceuticals Inc	QELBREE	viloxazine hydrochloride	17772-131	ETHYLCELLULOSE	2035-04-02

Qelbree Excipient Strategy and Commercial Opportunities in Viloxazine Extended-Release Products

Last updated: August 9, 2026

Qelbree is a once-daily, nonstimulant extended-release capsule containing viloxazine hydrochloride. Its commercial differentiation depends on controlled release, pediatric administration flexibility, and a formulation that can be sprinkled over soft food without compromising extended-release performance. The principal excipient opportunities are controlled-release polymers, capsule and coating systems, pediatric sprinkle platforms, and generic formulations that replicate dissolution and food-effect performance.

What is Qelbree and how is it administered?

Qelbree is the U.S. brand name for viloxazine extended-release capsules. Supernus Pharmaceuticals markets the product for attention-deficit/hyperactivity disorder in patients aged 6 years and older.

Qelbree is available in four strengths:

Strength	Dosage form	Typical administration
100 mg	Extended-release capsule	Once daily
150 mg	Extended-release capsule	Once daily
200 mg	Extended-release capsule	Once daily
400 mg	Extended-release capsule	Once daily in adults, when clinically appropriate

The capsule may be swallowed whole or opened and sprinkled over applesauce or pudding. The granules must not be crushed or chewed because mechanical disruption can alter the extended-release profile.[1]

Viloxazine is a selective norepinephrine reuptake inhibitor with additional activity at serotonin receptors. Unlike stimulant ADHD products, Qelbree is not a controlled substance under the U.S. Controlled Substances Act.[1]

What excipients are used in Qelbree capsules?

The Qelbree label identifies a relatively conventional solid oral excipient system. The inactive ingredients include:

• Colloidal silicon dioxide
• Hypromellose
• Magnesium stearate
• Microcrystalline cellulose
• Talc
• Capsule-shell materials, including gelatin and colorants depending on strength

The exact commercial formulation also relies on processing variables, particle-size control, granule architecture, coating thickness, and capsule-fill uniformity. The inactive-ingredient list alone does not disclose the complete formulation strategy or the manufacturing sequence.[1]

What does each Qelbree excipient do?

Excipient or material	Likely formulation role	Commercial relevance
Hypromellose	Matrix former, binder, or release-controlling polymer	Central opportunity for alternative extended-release designs
Microcrystalline cellulose	Filler, dry binder, and granulation aid	Broad supplier base and low substitution barrier
Colloidal silicon dioxide	Glidant and moisture-flow aid	Supports content uniformity and capsule-filling performance
Magnesium stearate	Lubricant	Requires control because excess lubrication can affect dissolution
Talc	Processing aid and anti-adherent	May support granule handling and manufacturing robustness
Gelatin and colorants	Capsule shell and product identification	Potential opportunity for vegetarian, non-gelatin, or differentiated shells

Hypromellose is the most strategically important listed excipient because it can influence hydration, gel formation, diffusion, erosion, and release duration. Its grade, viscosity, particle size, concentration, and location within the dosage form can materially affect dissolution.

How does Qelbree’s extended-release excipient strategy work?

Qelbree uses a multiparticulate oral dosage form rather than a conventional immediate-release powder. The capsule contains drug-containing particles or granules engineered to release viloxazine over an extended period.

The commercial objective is to achieve:

1. Once-daily exposure.
2. Acceptable absorption across the gastrointestinal tract.
3. Reduced peak-to-trough fluctuation compared with immediate-release dosing.
4. Mechanical stability during capsule opening and sprinkling.
5. Consistent dissolution across the product’s labeled strengths.
6. Adequate stability under normal storage conditions.

A polymer-based matrix or coating system can control release through hydration and diffusion. A multiparticulate system may also reduce the risk that a single damaged unit produces a large dose release. The precise architecture is important because generic applicants must demonstrate pharmaceutical equivalence and bioequivalence to the reference product.

Why does the sprinkle option matter?

The sprinkle option expands use among pediatric patients who cannot swallow capsules. It also creates a technical barrier for generic developers because a substitute product must preserve:

• Particle size and dose uniformity after capsule opening.
• Adhesion and recovery from soft food.
• No-chew requirements.
• Extended-release behavior after administration with food.
• Stability during handling.
• Acceptable taste and mouthfeel.

A generic capsule that matches average pharmacokinetics but performs poorly as a sprinkle product may face labeling, usability, or clinical adoption problems.

What formulation patents protect Qelbree?

Qelbree’s key intellectual-property risk is likely concentrated in formulation and use claims rather than in the basic chemical identity of viloxazine. Viloxazine itself is an older compound, so composition-of-matter protection for the active ingredient is not the principal exclusivity driver in the United States.

Relevant patent categories include:

• Extended-release viloxazine compositions.
• Multiparticulate or coated-particle dosage forms.
• Once-daily dosing regimens.
• Treatment of ADHD with viloxazine.
• Pediatric dosing and administration methods.
• Drug-release profiles and pharmacokinetic targets.
• Manufacturing processes for drug-loaded particles or granules.

Orange Book-listed patents, if applicable, can support Paragraph IV litigation against an abbreviated new drug application. Method-of-use patents may create narrower exposure because a generic applicant can attempt a section viii “skinny label” that omits patented uses, although the commercial effectiveness of that strategy depends on the approved label and prescribing patterns.[2]

A transaction or litigation assessment should separate three issues:

IP issue	Commercial impact
Listed drug-product patent	Can delay ANDA approval or trigger Paragraph IV litigation
Method-of-use patent	May permit a carved-out generic label, subject to infringement risk
Unlisted formulation know-how	Can increase development cost but usually does not independently block approval
Manufacturing trade secret	Can raise process-replication costs and create supply risk
FDA regulatory exclusivity	Can delay ANDA submission or approval regardless of patent status

When does Qelbree lose FDA exclusivity?

Qelbree received FDA approval on May 26, 2021, under NDA 211964.[3] As a new chemical entity, it generally received five years of U.S. regulatory exclusivity, subject to statutory rules governing ANDA and 505(b)(2) submissions.

The principal federal milestones are:

Milestone	Date or status
FDA approval	May 26, 2021
Five-year NCE exclusivity	Generally runs to May 26, 2026
ANDA submission with Paragraph IV	Generally possible after four years, subject to NCE rules
Generic approval	Depends on patents, litigation, exclusivity, and FDA review
Patent expiry	Must be confirmed against current Orange Book records and issued patent status

The five-year NCE period does not guarantee market exclusivity through 2026 if a relevant patent expires later. Conversely, the end of NCE exclusivity does not guarantee immediate generic entry because listed patents, pediatric exclusivity, litigation stays, or regulatory review may remain relevant.

Qelbree received pediatric approval for ADHD in children and adolescents. Pediatric exclusivity can extend qualifying listed patents or regulatory exclusivity by six months if FDA requirements are met, although the commercial effect depends on the specific exclusivity record.[2]

What is the Orange Book status of Qelbree?

The FDA Orange Book is the controlling source for current listed patents, exclusivity codes, and approved drug-product information. Qelbree’s Orange Book analysis should examine:

• NDA 211964.
• Listed patent numbers and expiration dates.
• Any pediatric-exclusivity adjustment.
• Whether patents are composition, formulation, or method-of-use patents.
• The availability of Paragraph IV certification.
• Any approved 30-month litigation stay.

The formulation analysis should not rely solely on the product label. A label discloses inactive ingredients but does not identify every protected manufacturing parameter, particle architecture, coating sequence, or dissolution limitation.

For commercial planning, the most important distinction is between an early ANDA filing date and an actual generic launch date. An ANDA applicant may file a Paragraph IV certification before the end of NCE exclusivity, but FDA approval and launch remain subject to the exclusivity and patent framework.

Which companies are challenging Qelbree?

Qelbree faces potential competition from generic viloxazine ER developers, but a complete current list of Paragraph IV filers requires review of FDA ANDA litigation records, district-court dockets, and Supernus disclosures.

The competitive field includes:

• Generic pharmaceutical companies developing viloxazine ER capsules.
• Contract development and manufacturing organizations with multiparticulate coating capabilities.
• ADHD portfolio companies seeking nonstimulant alternatives.
• Companies developing liquid, sprinkle, orally disintegrating, or alternative modified-release products.

The most credible generic challengers are likely to have experience with:

• Hydrophilic matrix systems.
• Drug-layered pellets.
• Polymer-coated multiparticulates.
• Pediatric sprinkle products.
• In vitro-in vivo correlation.
• Complex oral dosage-form bioequivalence.

Qelbree is more technically demanding than a simple immediate-release capsule. A successful generic must match the reference product’s release mechanism, exposure, food effect, particle handling, and strength scaling.

What excipient commercial opportunities exist around Qelbree?

Controlled-release polymer supply

Hypromellose and related cellulose polymers are the clearest direct opportunity. Suppliers can compete on:

• Low- and high-viscosity grades.
• Narrow particle-size distributions.
• Consistent hydration behavior.
• Low bioburden and low endotoxin profiles.
• Regulatory documentation.
• Global supply continuity.
• Compatibility with high-drug-load granulation.

An excipient supplier that can demonstrate equivalent dissolution performance with lower polymer loading may create value for generic developers through reduced capsule fill mass and improved manufacturability.

Multiparticulate coating systems

Qelbree-type products create demand for coating technologies that provide:

• Uniform polymer deposition.
• Controlled permeability.
• Low agglomeration.
• Strong resistance to capsule-opening and sprinkle handling.
• Reproducible release across pH conditions.
• Scalable fluid-bed processing.

Commercial opportunities include aqueous polymer dispersions, pore-former systems, anti-tacking agents, and ready-to-use coating platforms.

Pediatric administration platforms

The sprinkle route is commercially significant. Product developers can pursue:

• Non-gelatin capsules.
• Smaller capsule sizes.
• Neutral-taste granules.
• Improved adhesion to applesauce or pudding.
• Single-dose sachets containing coated granules.
• Alternative pediatric modified-release forms.

Any new formulation must address the risk that a different food vehicle, particle size, or taste profile changes adherence and real-world persistence.

Alternative viloxazine dosage forms

Potential line extensions include:

• Oral granules.
• Sachets.
• Mini-tablets.
• Orally disintegrating dosage forms.
• Liquid formulations with modified-release particles.
• Lower-strength pediatric units.
• Combination products for ADHD-related symptoms.

These products may face formulation patents, clinical requirements, and regulatory questions concerning substitutability. They also could extend the commercial life of viloxazine beyond the original capsule format.

Excipient qualification and supply-chain services

Qelbree-type products need excipients with reliable lot-to-lot functionality. Service providers can monetize:

• Excipient characterization.
• Design-of-experiments studies.
• Dissolution method development.
• Stability testing.
• Extractables and leachables work for coatings.
• Regulatory support for novel or regionally different excipients.
• Dual-source qualification.

For a generic developer, supply continuity can be as important as nominal excipient price because changes in polymer grade can require comparability studies and regulatory notification.

How strong is the Qelbree formulation strategy?

Qelbree’s formulation position is stronger than a conventional immediate-release product because it combines modified release with pediatric sprinkle administration. Its main technical strengths are:

• Once-daily dosing.
• Multiparticulate flexibility.
• A nonstimulant mechanism.
• Use in children and adolescents.
• Potentially lower abuse-related concerns than stimulant products.
• A formulation that can be administered without swallowing the intact capsule.

Its principal vulnerabilities are:

• Viloxazine is an established active ingredient, limiting chemical novelty.
• Excipients such as hypromellose and microcrystalline cellulose are widely used.
• Generic developers have extensive experience with modified-release multiparticulates.
• Clinical differentiation against established ADHD therapies remains commercially important.
• A successful generic may reproduce performance without using identical excipients.

The formulation estate is strongest when claims cover the interaction of composition, release profile, particle structure, and administration method. Claims limited to standard excipients are easier to design around.

How does Qelbree compare with competing ADHD products?

Product	Active ingredient	Class	Dosage form	Controlled-substance status	Excipient opportunity
Qelbree	Viloxazine ER	Nonstimulant	Extended-release capsule with sprinkle option	Not controlled	Polymer matrices, coated granules, pediatric delivery
Strattera	Atomoxetine	Nonstimulant	Immediate-release capsule	Not controlled	Less emphasis on modified-release excipient systems
Intuniv	Guanfacine ER	Nonstimulant	Extended-release tablet	Not controlled	Matrix-tablet and pediatric dosage-form competition
Kapvay	Clonidine ER	Nonstimulant	Extended-release tablet	Not controlled	Matrix and tablet-coating technologies
Adderall XR	Mixed amphetamine salts ER	Stimulant	Extended-release capsule	Schedule II	Multiparticulate release and abuse-deterrence technologies
Vyvanse	Lisdexamfetamine	Stimulant prodrug	Capsule and chewable tablet	Schedule II	Taste masking, chewable systems, prodrug differentiation

Qelbree’s closest formulation competitors are extended-release products that address adherence and pediatric administration. Its closest therapeutic competitors are atomoxetine, guanfacine ER, and clonidine ER. Stimulants remain the larger commercial benchmark, but Qelbree can compete where prescribers seek a noncontrolled option or where stimulant tolerability is problematic.

What generic entry risks exist for Qelbree?

Generic entry risk is driven by five factors:

1. Expiry of NCE exclusivity.
2. Current Orange Book patent listings.
3. Paragraph IV filings and litigation outcomes.
4. Ability to demonstrate bioequivalence for a complex extended-release product.
5. Commercial willingness of pharmacies and payers to substitute.

The most likely generic launch scenarios are:

Scenario	Timing pressure	Commercial effect
No effective patent challenge	Delayed until relevant patent expiry	Preserves branded pricing longer
Successful Paragraph IV challenge	Potential early launch after litigation	Rapid price erosion and formulary substitution
Settlement with licensed or delayed entry	Fixed contractual date	Predictable but potentially earlier erosion
Skinny-label approval	Narrow initial indication coverage	Lower direct exposure, subject to prescribing behavior
Multiple generic approvals	Rapid competition	Greater discounting and inventory substitution

A generic developer’s main technical barrier is not the inactive-ingredient list. It is reproducing the reference product’s release behavior and pediatric sprinkle performance while meeting FDA requirements for complex extended-release products.

What revenue exposure does Qelbree create?

Qelbree revenue is exposed to:

• Generic substitution after regulatory exclusivity ends.
• Reimbursement pressure from nonstimulant alternatives.
• Prescriber preference for established ADHD therapies.
• Payer step-edit requirements.
• Pediatric persistence and adherence.
• Expansion into adult ADHD.
• New dosage forms and line extensions.

The commercial value of the excipient strategy extends beyond manufacturing cost. A robust sprinkle product can improve adherence, support pediatric use, and reduce switching to alternative therapies. The value is highest if the formulation supports reliable once-daily administration without adding substantial preparation burden for caregivers.

Key Takeaways

• Qelbree is viloxazine hydrochloride in a once-daily extended-release capsule.
• Its main excipient strategy uses a multiparticulate modified-release system with hypromellose, microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate, and talc.
• Hypromellose grade and processing are central to release control and generic design-around analysis.
• The sprinkle option creates additional technical and commercial differentiation in pediatric ADHD.
• Qelbree received FDA approval on May 26, 2021, with five-year NCE exclusivity generally extending to May 26, 2026.
• Patent risk is likely concentrated in extended-release formulations, dosing methods, particle architecture, and manufacturing processes.
• The strongest commercial opportunities are controlled-release polymers, aqueous coating systems, pediatric granules, non-gelatin capsules, and excipient qualification services.
• Generic entry depends on Orange Book patents, Paragraph IV litigation, bioequivalence, and the ability to replicate sprinkle and food-effect performance.

FAQs

Can Qelbree be reformulated as a liquid?

A liquid Qelbree product would need to preserve extended-release behavior, dose uniformity, chemical stability, taste acceptability, and labeled administration conditions. A conventional aqueous solution would generally be incompatible with extended release unless the product used coated particles or another modified-release carrier.

Are Qelbree excipients protected by patent rights?

Individual excipients such as hypromellose and microcrystalline cellulose are established pharmaceutical materials. Patent protection is more likely to attach to their use in a specific viloxazine formulation, particle structure, release profile, or manufacturing process than to the excipients themselves.

Can a generic use different excipients from Qelbree?

Yes. FDA approval does not generally require an ANDA applicant to use identical inactive ingredients. The proposed formulation must satisfy inactive-ingredient requirements and demonstrate pharmaceutical equivalence, bioequivalence, stability, and appropriate performance.

Does sprinkling Qelbree on food change its release?

The labeled administration method is designed to permit sprinkling without chewing the particles. Crushing or chewing can disrupt the extended-release system and alter drug release. The selected food vehicle and handling process should follow the FDA-approved labeling.[1]

Is viloxazine suitable for a non-gelatin capsule opportunity?

Potentially. A non-gelatin shell could support vegetarian or religious-diet positioning, but the substitute shell must maintain moisture protection, mechanical performance, stability, capsule opening, and compatibility with the filled multiparticulate formulation.

References

1. U.S. Food and Drug Administration. (2024). Qelbree (viloxazine hydrochloride) extended-release capsules: Prescribing information. Supernus Pharmaceuticals, Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2021). Qelbree approval letter, NDA 211964. Center for Drug Evaluation and Research.

4. Supernus Pharmaceuticals, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

5. U.S. Food and Drug Administration. (2024). Inactive ingredient database. Center for Drug Evaluation and Research. https://www.accessdata.fda.gov/scripts/cder/iig/